MedTrace Logo

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

NCT04789408 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-11

Study results available
· View outcomes & findings →

Summary

The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Conditions

Interventions

DRUG

Cyclophosphamide

Administered intravenously

DRUG

Fludarabine

Administered intravenously

BIOLOGICAL

KITE-222

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Sponsors & Collaborators

  • Kite, A Gilead Company

    lead INDUSTRY

Principal Investigators

  • Kite Study Director · Kite, A Gilead Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2024-05-18
Completion
2024-05-18
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04789408 on ClinicalTrials.gov